Physician profile
James W Baker
NPI 1710982293
$3,937.46
in general payments reported to CMS, 2019-2025
25 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $890 · 2021: $44.71 · 2022: $332 · 2023: $602 · 2024: $682 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.89 |
| Education | $237.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst Pharmaceuticals, INC. | $875.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $460.31 | 2019-2025 | Dupixent |
| Csl Behring | $411.47 | 2024-2025 | Andembry, Hizentra, Haegarda |
| Genzyme Corporation | $399.74 | 2023-2025 | |
| Genentech USA, INC. | $287.56 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $235.25 | 2023-2025 | Takhzyro, Cuvitru |
| Astrazeneca Pharmaceuticals LP | $185.68 | 2023-2024 | Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $175.89 | 2020-2025 | Nucala, Trelegy Ellipta |
| Allergan, INC. | $140.58 | 2022 | |
| Galderma Laboratories, L.P. | $125.51 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $124.53 | 2023-2025 | Ayvakit |
| Incyte Corporation | $96.00 | 2025 | Opzelura |
| Biocryst US Sales Co., LLC | $75.64 | 2021-2025 | Orladeyo |
| Pfizer INC. | $48.14 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $43.42 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40.50 | 2024-2025 | Ebglyss |
| Cycle Pharmaceuticals INC | $38.21 | 2024-2025 | Sajazir |
| Abbvie INC. | $33.88 | 2022 | |
| Kaleo, INC. | $29.41 | 2022 | |
| Shire North American Group INC | $25.81 | 2019 | |
| Alk-Abello, INC | $25.55 | 2024 | Grastek, Odactra, Ragwitek |
| Pharming Healthcare, INC. | $20.91 | 2023 | Ruconest |
| Grifols USA, LLC | $20.29 | 2022 | |
| Merck Sharp & Dohme LLC | $18.18 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.